一分钟看懂
这是一项关于Metastic Thyroid Cancer的II 期研究，登记的药物或干预包括68-Gallium-DOTATATE-PET/CT，当前状态为招募中。登记地点显示中国Bethesda有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
68-Gallium-DOTATATE-PET/CT · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Institutes of Health Clinical Center · Bethesda
公开的入选条件
- Data prospectively collected from the 28 subjects enrolled under this protocol, and data from 26 subjects collected under 77-DK-0096 and/or 00-CH-0093 will be analyzed. Among the 26 subjects prospectively evaluated under 77-DK-0096 protocol, 21 out of 26 had r
- Patients with HTC, DTC, and MTC will be identified by the investigators. The potential candidates for the study will be screened for eligibility to participate in the study and invited to sign the Research 68Ga-DOTATATE PET/CT imaging informed consent form. Th
- In order to be eligible to participate in this study, an individual with DTC (including HTC) must meet all of the following criteria:
- * Male or female, aged \>18 years.
- * Patients with established thyroid cancer diagnosis presenting with either:
- Locally advanced or distant metastases, which are RAI-non-avid based on the or diagnostic or post-treatment whole body scan (WBS)
- --Patients with RAI-non-responsive disease, who have the evidence of disease progression defined by RECIST 1.1 criteria after therapy with RAI.
- In order to be eligible to participate in this study, an individual with MTC must meet all of the following criteria:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04927416；登记信息更新于 2026-09-16。